Chapter 11 filing won't affect Stimulon partnerships

Chapter 11 filing won't affect Stimulon partnershipsCambridge Biotech Corp. said its relationships with the numerous licensees of its Stimulon adjuvant won't be affected by its filing for Chapter 11 bankruptcy protection.

The Worcester, Mass., company - whose Chapter 11 announcement last week culminated a series of financial setbacks that erupted in January - has decided to focus on its adjuvant and drug delivery businesses, downplaying its diagnostics business...